DSS Bets on Turnaround as Valuation Disconnect Puzzles Leadership

ROCHESTER, NY – April 15, 2026 – In a direct appeal to shareholders, DSS, Inc. (NYSE American: DSS) Interim CEO Jason Grady today painted a picture of a company fundamentally stronger than its market performance suggests. A detailed letter outlined significant operational progress and financial discipline throughout 2025, contrasting sharply with a stock price that has fallen 36% over the last six months.

Grady addressed the elephant in the room, acknowledging a persistent disconnect between the company's internal improvements and its public valuation, which currently hovers at a modest $9.4 million. “Over the past six months, our stock performance has not fully reflected the progress we have made inside DSS,” Grady stated in the letter. He attributed the market’s tepid response to “legacy financial results, balance sheet considerations, and the complexity of historically operating across multiple business segments.”

The company is betting that a leaner cost structure, combined with strategic growth in its core divisions and a pivotal move for its biotech arm, will finally force investors to take a second look.

A Tale of Two Realities: Progress vs. Perception

The numbers presented by DSS depict a company in the midst of a significant operational overhaul. Total costs and expenses for 2025 plummeted 43% to $35.2 million from $61.7 million in the prior year. This was not merely belt-tightening; it was accompanied by targeted growth. Total revenue for 2025 climbed 8.7% to $20.76 million, and the company’s net loss, while still substantial at $23.93 million, was nearly halved from the previous year.

This progress was driven by strong performance in two of its four core segments. The Product Packaging division, a cornerstone of the business, saw its printed products revenue jump 12% to $18.1 million. Meanwhile, the Securities and Investment Management arm, Sentinel Brokers, delivered a striking 39% increase in commission revenue.

Despite these positive indicators, Wall Street remains unconvinced. The company’s stock trades under a dollar, and external analysis highlights the reasons for investor caution. DSS still carries a significant debt burden of over $40 million, and reports indicate a key $37 million loan is in default. Furthermore, the company continues to burn through cash and operates with a negative gross profit margin, leading to a “WEAK” financial health rating from some analysts. This challenging financial backdrop helps explain why, as Grady noted, “limited institutional ownership and low trading volume have created an environment where short-term sentiment can outweigh fundamentals.”

The Biotech Catalyst: Unlocking Value Through Impact BioMedical

At the heart of DSS’s strategy to bridge this valuation gap is Impact BioMedical, its biotechnology subsidiary. After spinning the unit out in September 2024, DSS is now advancing a proposed reverse merger involving the biotech firm. This complex maneuver is designed to create a more liquid and visible public vehicle for Impact BioMedical, which boasts a portfolio of 9 issued patents and over 40 pending applications.

By separating the high-growth potential of the biotech business, DSS hopes to crystallize its value in a way that is currently obscured within the diversified parent company. The letter describes the move as a key example of “unlocking value within high-potential businesses while maintaining strategic alignment.” For DSS, which retains a stake, a successful transaction could provide a significant non-dilutive capital infusion and validate its strategic vision.

However, the move is not without risk. DSS’s balance sheet carries approximately $17 million in net intangible assets tied to Impact BioMedical. The ultimate value of these assets hinges on the biotech firm's ability to successfully license and commercialize its technology, a notoriously difficult path. The proposed reverse merger is a critical step in that journey, and its outcome will be a major test for Grady’s value-unlocking strategy.

Building a Foundation in Packaging and Finance

While the biotech play captures attention, the company’s turnaround is equally dependent on the steady performance of its more traditional businesses. Premier Packaging, the company’s packaging division, has become its revenue engine, responsible for the vast majority of its 2025 sales. The division is capitalizing on strong demand in the medical device, food and beverage, and wellness sectors. DSS is now actively evaluating acquisitions in the folding carton space to build scale, expand its geographic footprint, and broaden its capabilities.

Simultaneously, the Sentinel Brokers division is being transformed from a simple revenue contributor into a more sophisticated capital markets player. In 2025, the firm received crucial FINRA approval to act as an underwriter and selling group member for corporate securities offerings, including IPOs. This significantly expands its service offerings, allowing it to participate more directly in lucrative capital markets transactions and diversify its revenue streams beyond simple trading commissions.

These foundational segments provide stability and tangible growth, balancing the higher-risk, higher-reward nature of the biotech venture. However, not all segments are firing on all cylinders. Research indicates the company's Commercial Lending arm has faced headwinds, with declining revenues as some real estate assets faced vacancy and loans went on non-accrual, underscoring the challenges of managing a complex, four-pronged enterprise.

As DSS moves forward, its leadership believes the deep disconnect between its operational footprint and its market value presents a unique opportunity. “Modest improvements in profitability, capital structure, or strategic clarity can have an outsized impact on shareholder value,” Grady concluded in his letter. The strategy is now laid bare: prove the turnaround with consistent financial results, execute the biotech value play, and grow the foundational businesses. The coming quarters will reveal whether this multi-faceted plan is enough to finally win the market’s confidence.